Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2018

View Archived Issues

Mitochondrial pathophysiology linked to myocardial senescence

Targeting metabolism, not hormones, in prostate cancer

How MRSA makes itself look sweet

MATCH, a first-in-human, phase I, dose-escalation trial in cirrhosis

Phase II results presented for mocetinostat plus durvalumab in patients with NSCLC

Results from phase I/II study of INT230-6 in solid tumors

Arcus Biosciences patents adenosine A2A/A2B receptor antagonists

TAS-1553 demonstrates efficacy in preclinical models of hematological and solid tumors

First-in-human data presented for FAZ-053 monotherapy or in combination with spartalizumab

AB-122 demonstrates preliminary safety and activity in solid tumors

Improved mouse model of type A hepatic encephalopathy devised

European Commission approves pegfilgrastim biosimilar Pelmeg

MicuRx initiates phase II study of contezolid acefosamil in ABSSSI

Phase III study of VR-475 in severe uncontrolled asthma does not meet primary endpoint

Deleterious telomerase mutations identified in patients with end-stage liver disease

Juluca approved in Japan

Poxel begins part 2 of phase Ia study of PXL-065 for NASH

Pulmonary arterial hypertension model allows study of early intervention

PIONEER 6 trial of oral semaglutide demonstrates favorable CV safety profile

FDA places clinical hold on IND for first U.S. trial of ZGN-1061

RNAi therapeutic VIR-2218 begins phase I/II study for chronic HBV infection

Theravance initiates phase I study of TD-8236 by inhalation for asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...